FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) will start clinical trials of conversational dementia diagnosis support AI system (AI medical device) and obtain regulatory approval in March. On the 3th, we submitted a clinical trial report to the Pharmaceuticals and Medical Devices Agency (PMDA).

　The conversational dementia diagnosis support AI system utilizes language-based AI technology to perform neuropsychological tests (MMSE, etc.) for dementia, which were previously considered difficult unless a doctor has experience in dementia treatment. , It is a system that can be performed from a very natural daily conversation.AI medical devices that utilize linguistic AI technology have not been approved in any country, and if officially approved by the regulatory affairs, it will be the world's first linguistic AI medical device.By approving this system as a medical device, (XNUMX) early detection of dementia, (XNUMX) standardization of dementia tests, (XNUMX) reduction of physical and psychological burden on both patients and healthcare professionals, (XNUMX) digital medical care such as telemedicine. We believe that it can greatly contribute to the standardization and efficiency improvement of medical care.

Judgment flow by daily conversation using AI

　In Japan, which is facing a super-aging society, measures against dementia have become an important issue. FRONTEO aims to obtain early approval so that this system can contribute to clinical practice as soon as possible.

■ About conversational dementia diagnosis support system　URL: https://lifescience.fronteo.com/aidevice/dementia/

The conversational dementia diagnosis support system (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder (registered trademark: conceptencoder, reading: concept encoder)" between the patient and the doctor. It is a system that can screen for cognitive dysfunction from daily conversation for about 5 minutes.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I will. FRONTEO entered into a business alliance agreement with Kyowa Pharmaceutical Industry Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 10, aiming for early commercialization and early market penetration in the medical field.Patent registration number: Patent No. 2020

■ About Concept Encoder　URL: https://lifescience.fronteo.com/technology/conceptencoder/

"Concept Encoder (registered trademark: concept encoder, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6, 26 Obtained a first-class medical device manufacturing and sales license (permit number: 2021B1X13).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.